Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 161

The DOI matches its Crossref record.

EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.

Lencioni, Riccardo, Kudo, Masatoshi, Erinjeri, Joseph, Qin, Shukui, Ren, Zhenggang, Chan, Stephen, Arai, Yasuaki, Heo, Jeong, Mai, Ahn, Escobar, Jose, Lopez Chuken, Yamil Alonso, Yoon, Jung-Hwan, Tak, Won Young, Suttichaimongkol, Tanita, Bouattour, Mohamed, Lin, Shi-Ming, Żotkiewicz, Magdalena, Udoye, Stephanie, Cohen, Gordon, Sangro, Bruno · 2024 · Journal of Clinical Oncology

Abstract

LBA432 Background: For >20 years, TACE has been a standard of care for embolization-eligible uHCC; however, most people with uHCC treated with TACE progress within 1 year. Embolization creates a proinflammatory tumor microenvironment and increases VEGF signals; clinical studies have established the role of immune checkpoint inhibitors (ICIs; e.g. D) and VEGF inhibitors (e.g. B) in advanced HCC. Methods: In EMERALD-1 (NCT03778957; double-blind, global, Phase 3 study), participants (pts) with embolization-eligible uHCC, Child-Pugh A to B7 liver function, Eastern Cooperative Oncology Group performance status 0–1, and no evidence of extrahepatic disease were randomized 1:1:1 to the D+B+TACE, D+TACE, or TACE arms. TACE was cTACE or DEB-TACE (investigator choice). Pts received D (1500 mg) or placebo for D (Q4W) plus TACE. After completion of last TACE, pts received D (1120 mg) or placebo for D plus B (15 mg/kg) or placebo for B (Q3W). Primary endpoint was progression-free survival (PFS) for D+B+TACE vs TACE. Secondary endpoints included PFS for D+TACE vs TACE, overall survival (OS), objective response rate (ORR), time to progression (TTP), and safety for D+B+TACE or D+TACE vs TACE. PFS, ORR, and TTP were assessed by blinded independent central review (RECIST v1.1). Results: In total, 616 pts with BCLC Stage A (25.8%), Stage B (57.3%), and Stage C (16.1%) were randomized to D+B+TACE (n=204), D+TACE (n=207), or TACE (n=205). Demographic and baseline characteristics were generally balanced across arms. At final PFS analysis, the primary objective was met: PFS significantly improved for D+B+TACE vs TACE (median [m]PFS 15.0 vs 8.2 months [mo]; hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.61–0.98; p=0.032 [threshold 0.0434]). Results were consistent across most prespecified subgroups. The secondary endpoint of PFS for D+TACE vs TACE was not statistically significant (mPFS 10.0 vs 8.2 mo; HR, 0.94; 95% CI, 0.75–1.19; p=0.638). ORR was 43.6%, 41.0%, and 29.6%, and mTTP was 22.0, 11.5, and 10.0 mo for D+B+TACE, D+TACE, and TACE, respectively. No new safety signals were identified. In the D+B+TACE (n=154), D+TACE (n=232), and TACE (n=200) safety analysis sets, respectively, 32.5%, 15.1%, and 13.5% of pts had maximum Grade 3/4 treatment-related adverse events (TRAEs); 8.4%, 4.3%, and 3.5% discontinued due to TRAEs; and 0%, 1.3%, and 2.0% died due to TRAEs. Pts continue to be followed for OS. Conclusions: D+B+TACE is the first ICI-based regimen in a global Phase 3 trial to show statistically significant and clinically meaningful improvement in PFS, vs TACE, in pts with embolization-eligible uHCC. Safety was manageable and consistent with the safety profiles of D, B, and TACE in uHCC. D+B+TACE has the potential to set a new standard of care in uHCC. Clinical trial information: NCT03778957 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2024.42.3_suppl.lba432

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 161

Metadata

Authors
Lencioni, R., Kudo, M., Erinjeri, J., Qin, S., Ren, Z., Chan, S., Arai, Y., Heo, J., Mai, A., Escobar, J., Lopez Chuken, Y. A., Yoon, J.-H., Tak, W. Y., Suttichaimongkol, T., Bouattour, M., Lin, S.-M., Żotkiewicz, M., Udoye, S., Cohen, G., & Sangro, B.
Venue
Journal of Clinical Oncology
Published
2024-01-20
Volume
42
Issue
3_suppl
Pages
LBA432-LBA432
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4391091208
Cited by
161
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. https://app.cochat.ai/papers/10.1200/jco.2024.42.3_suppl.lba432
The paper
Lencioni, R., Kudo, M., Erinjeri, J., Qin, S., Ren, Z., Chan, S., Arai, Y., Heo, J., Mai, A., Escobar, J., Lopez Chuken, Y. A., Yoon, J.-H., Tak, W. Y., Suttichaimongkol, T., Bouattour, M., Lin, S.-M., Żotkiewicz, M., Udoye, S., Cohen, G., & Sangro, B. (2024). EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2024.42.3_suppl.lba432

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.